CD30: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
[[Category:Tumor markers]] | [[Category:Tumor markers]] | ||
[[Category:Lymphoma]] | [[Category:Lymphoma]] | ||
{{No image}} | |||
Revision as of 08:55, 10 February 2025
CD30 is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. CD30 is also known as TNFRSF8 and is a cell membrane protein of the tumor necrosis factor receptor superfamily. The encoded protein is a receptor for the lymphocyte-expressed ligand CD30L. CD30 is expressed on activated, but not on resting, T cells and B cells.
Function
CD30 has a role in cell proliferation and differentiation. It is thought to have a role in lymphoma pathogenesis and may have a role in the prognosis of some types of lymphoma. CD30 is also associated with anaplastic large cell lymphoma and is a defining feature of this type of non-Hodgkin lymphoma.
Clinical significance
CD30 is used in the diagnosis of lymphomas. It is expressed in Hodgkin's lymphoma, anaplastic large cell lymphoma, and embryonal carcinoma. CD30 expression is often associated with a poorer prognosis in non-Hodgkin lymphoma.
Therapeutic use
CD30 is the target of the FDA-approved antibody-drug conjugate brentuximab vedotin (Adcetris), used in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
See also
References
<references />
